Science Explorer Back to mapMap
Discussion
Institution · Metroplex Clinical Research Center

Most cited papers from Metroplex Clinical Research Center

Metroplex Clinical Research Center

What are the most cited papers from Metroplex Clinical Research Center?

The most cited paper from Metroplex Clinical Research Center is "A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate" (Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst et al., 1999), with 2,106 citations. Next come "Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis" (1,814) and "A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis" (1,752).

Showing 50 of 60 papers. Every paper with more than 100 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst et al. · New England Journal of Medicine Open access 28 Jan 1999 2,106
2 Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine Open access 26 Jan 2022 1,814
3 A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis Joan M. Bathon, Richard W. Martin, Roy Fleischmann et al. · New England Journal of Medicine Open access 30 Nov 2000 1,752
4 Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein Larry W. Moreland, Scott W. Baumgartner, Michael H. Schiff et al. · New England Journal of Medicine Open access 17 Jul 1997 1,650
5 Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Roy Fleischmann, Joel M. Kremer, John J. Cush et al. · New England Journal of Medicine Open access 8 Aug 2012 1,045
6 Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Ronald van Vollenhoven, Roy Fleischmann, Stanley B. Cohen et al. · New England Journal of Medicine Open access 8 Aug 2012 955
7 Tofacitinib versus Methotrexate in Rheumatoid Arthritis Eun Bong Lee, Roy Fleischmann, Stephen Hall et al. · New England Journal of Medicine Open access 18 Jun 2014 790
8 Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Stanley B. Cohen, Robert M. Levy, Michael I. Keller et al. · Arthritis & Rheumatism Nov 1999 617
9 Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Désirée M F M van der Heijde, Yoshiya Tanaka, Roy Fleischmann et al. · Arthritis & Rheumatism 24 Jan 2013 586
10 Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial Stanley B. Cohen, Robin K. Dore, Nancy E. Lane et al. · Arthritis & Rheumatism 25 Apr 2008 575
11 Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy Stanley Wallach, Stanley B. Cohen, Donald Malcolm Reid et al. · Calcified Tissue International Oct 2000 517
12 Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Roy Fleischmann et al. · The Lancet 216 authors 16 Jun 2017 506
13 Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis Joel M. Kremer, Zhanguo Li, Stephen Hall et al. · Annals of Internal Medicine 19 Aug 2013 452
14 Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial Roy Fleischmann, Aileen L. Pangan, In‐Ho Song et al. · Arthritis & Rheumatology 9 Jul 2019 449
15 Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial Mark C. Genovese, Roy Fleischmann, Bernard G Combe et al. · The Lancet Jun 2018 449
16 Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment Roy Fleischmann, Michael H. Schiff, Désirée M F M van der Heijde et al. · Arthritis & Rheumatology Open access 13 Oct 2016 434
17 Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu Joel M. Kremer, Ricardo Blanco, Marek Brzosko et al. · Arthritis & Rheumatism 19 Nov 2010 416
18 Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials Stanley B. Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases Open access 31 Jan 2017 397
19 Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study Josef S Smolen, Aileen L. Pangan, Paul E. Emery et al. · The Lancet 23 May 2019 386
20 Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion Larry W. Moreland, Rieke Alten, Filip E Van den Bosch et al. · Arthritis & Rheumatism Jun 2002 386
21 Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese et al. · Arthritis & Rheumatism 28 Sep 2011 379
22 A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Joel M. Kremer, Stanley B. Cohen, Bethanie E. Wilkinson et al. · Arthritis & Rheumatism Open access 17 Oct 2011 347
23 Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis et al. · Arthritis Research & Therapy Open access 5 Apr 2019 326
24 Toll-Like Receptor-2, but Not Toll-Like Receptor-4, Is Essential for Development of Oviduct Pathology in Chlamydial Genital Tract Infection Toni L. Darville, J O'Neill, Charles William Andrews et al. · The Journal of Immunology Dec 2003 295
25 Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study Mark C. Genovese, Roy Fleischmann, Alan Kivitz et al. · Arthritis & Rheumatology Open access 2 Mar 2015 272
26 A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee Stanley B. Cohen, Susanna Proudman, Alan Kivitz et al. · Arthritis Research & Therapy Open access 29 Jul 2011 249
27 American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3 Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel et al. · Arthritis & Rheumatology Open access 5 Dec 2020 244
28 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme Stanley B. Cohen, Ronald van Vollenhoven, Kevin L. Winthrop et al. · Annals of the Rheumatic Diseases Open access 28 Oct 2020 238
29 Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritis Stanley B. Cohen, Tien‐Tsai Cheng, Vishala L. Chindalore et al. · Arthritis & Rheumatism 29 Jan 2009 234
30 Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial Tom W. J. Huizinga, Roy Fleischmann, Martine Jasson et al. · Annals of the Rheumatic Diseases Open access 3 Dec 2013 228
31 Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data Philip J. Mease, Christina Charles‐Schoeman, Stanley B. Cohen et al. · Annals of the Rheumatic Diseases Open access 5 Aug 2020 224
32 Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis Gerd Rüdiger Burmester, Stanley B. Cohen, Kevin L. Winthrop et al. · RMD Open Open access Feb 2023 215
33 Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors Roy Fleischmann, Janet van Adelsberg, Yong Lin et al. · Arthritis & Rheumatology Open access 17 Nov 2016 215
34 A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann et al. · The Journal of Rheumatology 15 Jul 2016 211
35 Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis John Dudley Isaacs, Stanley B. Cohen, Paul E. Emery et al. · Annals of the Rheumatic Diseases Review 12 Jun 2012 199
36 Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates Robin K. Dore, Stanley B. Cohen, Nancy E. Lane et al. · Annals of the Rheumatic Diseases Open access 5 Sep 2009 194
37 Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study Stanley B. Cohen, Mark C. Genovese, Ernest Choy et al. · Annals of the Rheumatic Diseases Open access 5 Jun 2017 188
38 Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib Christina Charles‐Schoeman, Roy Fleischmann, Jean Davignon et al. · Arthritis & Rheumatology Open access 2 Dec 2014 188
39 Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme Stanley B. Cohen, Yoshiya Tanaka, Xavier Mariette et al. · RMD Open Open access Oct 2020 187
40 American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1 Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel et al. · Arthritis & Rheumatology Open access 29 Apr 2020 185
41 Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study Josef S Smolen, Gerd‐Rüdiger Burmester, Bernard G Combe et al. · The Lancet 15 Nov 2016 183
42 Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain Philip G. Conaghan, David John Hunter, Stanley B. Cohen et al. · Journal of Bone and Joint Surgery Open access 18 Apr 2018 176
43 Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis Stanley B. Cohen, S. Radominski, Juan Jesús Gómez-Reino et al. · Arthritis & Rheumatology Open access 21 Jul 2014 175
44 Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis M. Kloppenburg, CHARLES G. PETERFY, Ida Kristin Haugen et al. · Annals of the Rheumatic Diseases Open access 14 Dec 2018 174
45 Distinguishing rheumatoid arthritis from psoriatic arthritis Joseph Frank Merola, Luis R. Espinoza, Roy Fleischmann · RMD Open Open access Aug 2018 150
46 Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician Zoltán Szekanecz, Maya H Buch, Christina Charles‐Schoeman et al. · Nature Reviews Rheumatology Review 12 Jan 2024 141
47 How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Roy Fleischmann, Désirée M F M van der Heijde, Andrew S. Koenig et al. · Annals of the Rheumatic Diseases 21 Aug 2014 141
48 The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis Thomas J. Schnitzer, K. E. Truitt, Roy Fleischmann et al. · Clinical Therapeutics Oct 1999 137
49 A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis Mark C. Genovese, Stanley B. Cohen, David Wofsy et al. · The Journal of Rheumatology Open access Feb 2011 131
50 Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results Roy Fleischmann, Anne-Marie Halland, Marek Brzosko et al. · The Journal of Rheumatology Open access 15 Jan 2013 123

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.